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Abstract
Cryopreserved total skin allografts are a new therapeutic alternative for the
management of complex wounds. Their properties allow them to be classified as a
temporary coverage for some patients and as definitive in others. And they can be
an alternative option to the use of dermal regeneration templates.
Keywords: skin allograft, biological dressings, wound healing, skin substitutes,
dermal regenerators
1. Introduction
Historically, choosing the therapeutic options for the management of complex
wounds was based on the concept of the “reconstructive ladder”, in which recon-
structive methods were ranked by complexity and the simplest options capable of
solving the problem had to be chosen. The latter has evolved over time, with the
emergence of the “reconstructive elevator concept”, where a surgeon can ascend
directly to the appropriate level in order to obtain the best qualified reconstruction,
and due to the need of incorporating new advances in wound healing management
into the “reconstructive ladder” [1, 2].
The use of skin allografts (SA) for wound coverage began during the 19th
century. Currently occupy a predominant place within the temporary coverage
techniques, especially in burn patients, with little residual skin capital, and with
extensive clinical experience in other pathologies [3–7]. SA provide a physiological
lining to control the hydro electrolyte losses, reduce the pain and infection risk and
improve local bed conditions by promoting angiogenesis and the maturation of the
underlying granulation tissue [8, 9]. However, due to immunological processes,
they are usually rejected after 10–12 days and may eventually be a vector for
infectious diseases [10, 11].
Most of the SA come from cadaveric donor; are harvested as partial skin grafts
(Figure 1A) with a dermatome and are preserved using glycerol at high concentra-
tions, causing cellular death with the obtention of non-viable tissues [12, 13].
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2. Cryopreserved total skin allografts
2.1 Background
The low rate of human organ and tissue donation and the cultural and religious
restrictions for the use of cadaveric tissues in certain countries, have opened the
door to the pursuit of other sources of SA, particularly in patients who underwent
body contouring surgeries (abdominoplasty, reductive mammoplasty), either for
esthetic or reconstructive reasons. This allows the entire resected flap to be pro-
cured, allowing the obtention of total skin allografts (TSA) (Figure 1B) [ 14–17].
2.2 Tissue production
The process of obtaining TSA is initiated with the invitation of patients who are
candidates for body contouring surgeries to participate in the donation of the
redundant fatty skin flap, which would otherwise be a waste product. This repre-
sents the first difference with SA obtained from corpses, the TSA are obtained from
living donors. Donors are submitted under a health survey (Table 1), the absence of
exclusion criteria is verified (Table 2) and routine examinations for tissue donation
are performed (Table 3). All the above is assessed to guarantee the microbiological
safety of the tissues, which is mainly based on the selection of the donor, permitting
the rejection of infections or any biological agent that could cause diseases in the
recipient [18].
Figure 1.
A. Split-thickness skin graft B. Total skin allografts.
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YES NO
Are you in good health today?
Are you in generally good health?
Did you sleep at least 5 hours?
Have you drunk alcohol in the last 12 hours?
Have you donated blood in the last year?
Have you been told by a health professional that you cannot donate blood?
Have you been to another doctor’s office in the last 6 months?
Have you had a dental procedure over the last week?
Have you been hospitalized or operated during the last 6 months?
Have you received any transfusion in the last 12 months?
Have you had any blood tests in the last 12 months?
Do you have or have had any heart, lung, kidney or thyroid disease, hypertension, diabetes
mellitus, bleeding tendency or other illness?
Are you taking any medication on a regular basis in the last 6 months?
Have you taken aspirin or anti-inflammatory drugs in the last 3 days?
Have you had any injections or vaccinations in the last 4 days?
Have you had diarrhea in the last 7 days?
Have you ever had cancer?
Do you have a history of epilepsy, seizures or fainting?
Do you have or had hepatitis or have you turned yellow?
Have you had any tissue transplants or grafts?
Have you received growth hormone treatment before 1985?
Do you have a family history of Creutzfeldt-Jakob disease?
Do you or your family have a history of dementia, Alzheimer’s, Parkinson’s, Multiple
Sclerosis or another degenerative disease?
Do you or your family have a history of Chagas disease?
Have you had Malaria, Dengue fever or unexplained fever during or after a trip outside the
country?
Have you traveled outside the country in the last 3 years; if yes, where?
Have you had any tattoo, piercing, acupuncture or accidental needle stick or bloody syringe
in the last 6 months?
Have you tried any type of drug such as marijuana, cocaine, cocaine paste or other; if yes,
which ones and when?
Have you used illegal injectable or inhalant drugs over the last 12 months?
Have you had sexual intercourse with anyone who has ever injected drugs?
Have you had sexually transmitted diseases such as Syphilis, Gonorrhea or other in the last
12 months?
Have you had more than one sexual partner in the last 12 months?
Have you had sexual intercourse with a new partner in the last 6 months?
Have you had sexual contact with persons with Hepatitis, HIV or HTLV in the last
12 months?
Have you paid or received money, drugs, or anything else for sex in the last 12 months?
Have you been exposed to the risk of becoming infected with the AIDS virus?
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It is important to mention that patients submitted to bariatric surgery with a
secondary weight loss, have cutaneous structure and histological changes. Including
a lower fibroblast and elastin concentration and collagen fiber organization, sites of
chronic inflammation, sebaceous glands infections and metalloproteinases levels
similar to the skin of patients with cancer and burns. Therefore, it is expected that
the quality of TSAs from this group of patients will be lower [19, 20]. After the
donor selection, the process is divided into 10 stages: 1) surgical procedure/body
contouring surgery, 2) procurement itself, 3) packaging and identification, 4) stor-
age, 5) transport to the processing center, 6) processing, 7) cryopreservation/quar-
antine, 8) validation, release, records, 9) transfer and 10) clinical use. All of the
above must be within the framework of an organ and tissue donation program that
permits the generation and guarantee products of high: biological quality, sanitary
safety and therapeutic value [21].
2.2.1 Surgical procedure/body contouring surgery
The skin processing is performed in the operating room, at the same time as the
body contouring surgery, with all asepsis and antisepsis measures, under general
anesthesia and by the same surgical team. After the redundant skin marking and the
adipose skin flap dissection, the resection of the flap is performed. Subsequently,
two teams are formed: one finishes the body contouring surgery and the other, on a
separate surgical table, performs the skin procurement.
2.2.2 Skin treatment
The dissected adipose skin flap is placed on a separate operating table. Total skin
procurement (including dermis) is performed, removing the fat from the deeper
dermis with scissors (Figure 2). Tissue samples (3) are also taken for current
(aerobic), anaerobic and fungal culture. The procured skin is placed in a sterile
container with 500 cc of physiological saline solution with 1 g of Cloxacillin and
80 mg of Gentamicin, hermetically closed, making sure the skin is completely
submerged. This process of the allograft obtention gives the second distinctive
characteristic to the TSAs: they are total skin allografts.
2.2.3 Packaging and skin identification
The vials containing the skin are stored in double sterile bags of at least 90
microns. Each vial is hermetically sealed, removing as much air as possible, and
labeled with the tissue code and the date and time of processing.
2.2.4 Skin storage
The skin is transferred from the operating room to a temporary storage place in a
refrigeration unit, in order to maintain the temperature between 2 and 8°C.
YES NO
Are you donating tissue so that you can be tested for AIDS?
Have you been offered money to donate your tissue?
HIV: human immunodeficiency virus; HTLV: human T-lymphotropic virus; AIDS: Acquired immunodeficiency
syndrome.
Table 1.
Living tissue donor questionnaire.
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Exclusion criteria:
a. For infectious diseases
• Patients with history or carriers of HIV/AIDS.
• Patients with a history of Hepatitis B or C.
• Patients with a history of active Tuberculosis.
• Patients diagnosed with Syphilis or positive VDRL.
• Patients diagnosed with HTLV I and II.
• Patients diagnosed with Chagas disease.
• Patients with diagnosis of Rabies, Congenital Rubella and Malaria.
• Patients diagnosed with untreated bacterial or fungal endocarditis.
b. For central nervous system diseases
• Degenerative diseases







b. Viral, fungal or parasitic meningitis.
c. Bacterial meningitis.
d. Progressive multifocal leukoencephalopathy.
e. Subacute sclerosing panencephalitis.
f. Active viral encephalitis or encephalitis of unknown cause.
g. Fungal or parasitic encephalitis.
c. For presence of cancer and/or tumors
• History of neoplasia except for cervical uterine cancer in situ.
• Lymphadenopathy for more than one month.
• Lymphomas, lymphosarcomas
• Leukemias.
• Metastasis of primary or secondary malignant tumors (lung, breast, cervical, colon,
prostate, squamous cell, melanomas, lymphomas, leukemias, central nervous system,
among others).
d. Other pathologies
• Patients who have been treated with growth hormone.
• Patients with Hemophilia.
• Patients carriers of autoimmune diseases or Mesenchymopathies such as Rheumatoid
Arthritis, Systemic Lupus Erythematosus.
• Patients who have been treated with prolonged corticosteroid therapy.
• Any suspicious skin alteration.
e. Behavioral:
• Unsafe sexual behavior.
• Drug abuse (including intravenous, intramuscular and subcutaneous).
• Commercial sex workers.
• Inmates.
• Individuals with tattoos, (or) body piercing performed in the last 6 months.
• Individuals from whom no history of sexual behavior can be collected.
f. Specific skin criteria:
• Skin contaminated by toxins.
• Pyoderma.




• Structurally damaged skin (due to autoimmune or collagen diseases).
HIV: human immunodeficiency virus; HTLV: human T-lymphotropic virus; AIDS: Acquired immunodeficiency
syndrome; VDRL: Venereral Disease Research Laboratory.
Table 2.
Exclusion criteria for skin donation.
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2.2.5 Skin transportation
The skin is sent for processing, in our particular case, to the National Tissue
Bank (NTB), always within 36 hours from harvesting, assuring the container main-
tains a temperature between 2 and 8°C.
2.2.6 Processing
The TSAs are prepared in the NBT as implants, following two stages: In the first
one, the measurement of the flap is conducted, performing cuts in segments of
1.Hepatitis B surface antigen.
2.Antibodies against Hepatitis C.
3.Antibodies against HIV.
4.VDRL
5.HTLV I and II.
6.Chagas.
7.Cultures intraoperative
• Standard culture (aerobic)
• Anaerobic culture
• Mycotic culture.





Procurement of total skin with scissors from redundant adipose skin flap.
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different sizes according to the request; for example, in an average abdominoplasty,
approximately 300 cm2 of useful surface are obtained.
Subsequently, a revision of the shaving, washing cycles (to reduce the microbial
load), obtention of sample number 2 for cultures (the first one was intraoperative)
and immersion in cryopreservative solution for 1 hour are performed. In the second
stage, the preparation, cutting, measurement, packaging and labeling of each
obtained flap is conducted. Samples number 3 and 4 are taken for culture, which are
performed during the packaging stage. Finally, a 5th sample is taken, also for
culture, as a backup.
2.2.7 Cryopreservation and quarantine
Cryopreservation freezes the TSAs in the presence of a cryoprotectant (10%
glycerol), which prevents the crystallization effects while maintaining viability over
time after freezing. Viability being understood as the capacity of a biological unit to
remain alive. The cryopreserved total skin allograft (CTSA) is kept frozen at 80°C
awaiting the results of serial cultures until irradiation. The latter is performed with a
dose of 25 to 28 kGy, in dry ice to maintain the cold chain, being a complementary
procedure for tissue sterilization. The viability of the tissues obtained gives the third
distinctive characteristic to CTSAs, which is fundamental for the clinical results
[22, 23].
2.2.8 Validation, release and records
An adequate quality management system requires having a dossier or record of
each tissue processed, which allows the evaluation of each of the steps from the
generation to the implantation of the CTSAs in the recipient, permitting the
monitorization and traceability. Once the donation, procurement and processing
procedures have been reviewed and the microbiological results have been verified,
the tissues are released for clinical use.
2.2.9 Transportation
Following the tissue release, they are transferred for clinical use on dry ice,
maintaining the cold chain (80°C).
2.2.10 Clinical use
In the preoperative period, the size of the defect to be covered should be calcu-
lated in order to choose the CTSAs. The CTSAs should be washed 3 times with
warm saline (no more than 40°C) to remove cryoprotectants. The wound bed is
prepared by resection of necrotic, devitalized tissues and areas with granulation
disorder. The CTSAs is fixed with stitches and/or brackets associated with negative
pressure therapy [24].
3. Clinic
The CTSA has an initial attachment similar to an autologous skin graft, to later
evolve towards rejection, at 21 days average, which is clinically evidenced by color-
ation change and the formation of a superficial necrotic eschar. When the latter is
removed, it exposes vital tissue adhered to the host (Figure 3).
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This is evidenced histologically in the CTSAs by necrosis foci with infiltration
mainly of nuclear polymorphs (Figure 4a) and in the recipient bed by the presence
of an interface rich in fibroblasts and neoformation vessels (Figure 4b).
This interface or neo-dermis is also visualized with imaging studies; in magnetic
resonance imaging (MRI) CTSAs can be seen with a superficial non-catching com-
ponent and a deep component that is enhanced by the contrast medium, similar to
the vascularized dermis (Figure 5) [25]. For SA, it had already been described that
some elements of the dermis, mainly fibroblasts, could be permanently integrated
into the host, with exceptional situations of complete attachment and absence of
rejection of the SA. The most mediatic case involved Sir Winston Churchill, who
during the Nile War, donated skin and it was grafted to a wounded comrade and
“remains there to this day and has lasted well in many ways. Myself, keep the scar as
a souvenir.” [26–28].
CTSAs maintain the entire donor dermis, which participates in the proliferation
of a neo-dermis rich in fibroblasts and neoforming vessels, also acting as a scaffold
and a biological inducer in the wound bed. CTSAs have been shown in xenograft
models to promote angiogenesis and type 1 collagen production without eliciting a
significant fibrotic response [29]. Rejection of the CTSAs should not be interpreted
Figure 3.
Diabetic patient, 68 years old, with flap necrosis after transmetarsal amputation. a. Coverage deficit with bone
exposure associated with disordered granulatory tissue. b. Coverage with CTASs. c. Evolution CTASs after
28 days. d. Receiving bed after escharectomy of superficial part of CTASs. e. Partial skin autograft, result at day
7, which was subsequently lost in its entirety and managed with advanced healing. f. Result: 4 months after
initial surgery.
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as a therapeutic failure, but as a stage of what we have called intermediate coverage.
Since part of the CTSAs is lost and part adheres to the recipient bed, obtaining an
interface of neodermis allows the completion of the definitive coverage with an
autograft and a complete healing by second intention. This also produces a second-
ary contraction of the wound, reducing size of the defect.
The increased survival of seriously burnt patients with severe sequels, mainly
due to the limited contribution of the autologous partial skin graft dermis and
second intention scarring of the burnt skin, was the main motive for the dermal
matrix development. Currently, available dermal substitutes (biologic, synthetic or
biosynthetic origin) are fundamentally used as a scaffolding or biocompatible
structural support, that is colonized by the patient’s cells in order to form a
neodermis, which is practically identic in structure as the receipt’s dermis [ 30–34].
Figure 4.
a. Histology. Hematoxylin/eosin stain. CTSAs at the time of escharectomy (21 days). Circled are shows
infiltration of nuclear polymorphs, necrosis areas. b. Post-CTSAs receptor bed. Black arrow: Fibroblasts, red
arrow: Neoformation vessels.
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It is important to emphasize that dermal regeneration templates share various
advantages with CTSAs, including: a) immediate wound closure, thus avoiding
fluid loss and restoring the functional barrier of the skin, b) coverage of structures
Figure 5.
Magnetic resonance images of the foot in the sagittal plane enhanced in STIR -short tau inversion recovery- (a),
T1 (b) and T1 with fat saturation and contrast medium (c), showing the graft with a superficial non-
capturing component (white arrow) and a deep component that enhances with the contrast medium (yellow
arrow) similar to the vascularized dermis. Between the latter and the bone tissue, there is low signal material
with discrete enhancement (red arrow). (m2: Second metatarsal; m3: Third metatarsal).
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such as bone, cartilage and tendons and c) better scar quality and elasticity. But they
differ mainly in the high cost of dermal regeneration templates, which is the main
reason for their limited use in clinical practice, and the fact that they necessarily
Patient Age Genre Diagnosis Evolution
1 68 Y Masc Diabetic foot.
Transmetatarsal
amputation
Surgical debridement / bone resection / CTSA /
Scarectomy / Split-thickness skin graft / graft loss /
Advanced wound healing / Figure 3.
2 26 Y Masc Complex wound of the
leg
Surgical debridement / CTSA / Advanced wound
healing / Complete healing and closure
3* 53 Y Fem Relapsing
Dermatofibrosarcoma of
the scalp
Tumor resection / Skull Fenestration / CTSA /
Advanced wound healing. Figure 6.
4 55 Y Masc Diabetic foot.
Transmetatarsal
amputation
Surgical debridement / CTSA / Scarectomy / Split-
thickness skin graft / Loss of follow-up
5 70 Y Masc Abdominal sepsis. Open
abdomen
Complicated inguinal hernia / abdominal sepsis /
multi-organ failure / contained laparostomy, CTSA
/ clinical improvement/ extubation / Death due to
pneumonia
6* 2 M Masc Premature. Necrotizing
enterocolitis. Contained
laparostomy.
Premature 30 weeks / Dysfunctionalisation of
intestinal transit / evisceration (2 occasions) /
Contained laparostomy / CTSA / Para-ostomal
hernia and inguinal hernia. Periostomal and
inguinal hernioplasty. Figure 7.
7 60
Y
Masc Diabetic foot Surgical debridement / scarectomy / CTSA / Split-
thickness skin graft / 90% success / Loss of follow-
up
8 49 Y Masc Diabetic foot Surgical debridement / scarectomy / CTSA / Loss of
follow-up
9 57 Y Masc Skin stripping of the leg Scarectomy / CTSA / Split-thickness skin graft /
100% success.
10* 3 M Masc Premature. Necrotizing
enterocolitis. Contained
laparostomy.
Premature 30 weeks / CTSA replacement /
Abdominal wall continent / Second intention
healing. Figure 7.
11* 53 Y Fem Relapsing
Dermatofibrosarcoma of
the scalp
CTSA replacement in the central área / No
autologous graft due to absence of neodermis in
central area (initial bone wax in this area).
Figure 6.
12 75 Y Masc Melanoma of the cheek Melanoma (biopsy confirmed) resection. Local flap
reconstruction.
13 83 Y Masc Melanoma of the
forearm
Melanoma resection. Staging in process.
14 56 Y Masc Diabetic foot Surgical debridement / bone resection / CTSA /
Scarectomy / Split-thickness skin graft / Advanced
wound healing / complete wound closure
15 31 Y Fem Necrotizing fasciitis of
the forearm
Surgical debridement / CTSA / Awaiting progress
for skin autografting.
Years (Y), Months (M), Femenine (Fem), Masculine (Masc), CTSA: Cryopreserved total skin allograft. * Patient
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require a second time for skin autografting. Regarding the latter is that CTSAs can
be used as an alternative to dermal regeneration templates [35, 36].
4. Clinical experience
Our clinical experience was initiated on August 1st, 2020 and persists to the date.
Mainly following the pursuit of cutaneous coverages for seriously burnt patients,
given the lack of dermal regeneration matrix since their high cost and limited
availability. The latter is supported by the disposal of concomitant residual abdom-
inal skin grafts following abdominoplasty surgeries. The donor sample was consti-
tuted by fourteen female patients, of 31 to 55 years with an average age of 40 years.
The receipt sample was composed by 13 patients (two patients underwent two
surgical procedures), ages ranging from 2 months to 83 years. With the following
diagnosis: Diabetic foot (5), contained laparostomy (2) complex extremities
wounds (3), relapsed scalp sarcoma (1) and melanoma (2) [37]. Clinical evolution is
summarized in Table 4.
Figure 6.
Female patient, 53 years old. With a history of dermatosarcoma of the scalp. With resection and subsequent
reconstruction with local flaps and partial skin grafts. Tumour recurrence. a. Dermatosarcoma of the scalp. b.
Defect of coverage post resection. c. Fenestration of the skull. d. CTSA 30 days. e. CTSA 60 days f. CTSA 150
days, completely healed wound by second intention.
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5. Specifications
The therapeutic uses of CTSAs can be numerous. As we previously stated, we
emphasize in our experience the diabetic foot, extensive and complex coverage
deficits, contained laparotomies and post skin tumor resections, awaiting the biopsy
results for an eventual margin enlargement and reconstruction (Figures 6 and 7)
[38–42]. CTSAs can cover bone, cartilage and tendon exposures, being a simple
alternative for the management of complex wounds, becoming an intermediate
coverage for some patients and definitive for others.
6. Conclusions
The distinctive characteristics of CTSAs (from living donor, full-thickness skin,
and cryopreserved, therefore viable tissues) permits the obtention of a new type of
Figure 7.
30-week preterm infant. The patient evolves with necrotizing enterocolitis, requiring intestinal transit
defunctionalization and evisceration on two occasions. a. Laparotomy contained. b. Immediate postoperative
CTSA on open abdomen. c. Postoperative 21 days. d. Postoperative 35 days. e. Postoperative 60 days, protrusion
of paraostomal hernia associated with Valsalva is observed, however the CTSA area shows continent, in
addition to smaller size. f. Postoperative 90 days with healing by second intention, without intra-abdominal
protrusion. Paraostomal hernias and transit reconstitution, associated with CTSA change performed on day 70.
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coverage, which we have called intermediate coverage, easy to use, more econom-
ical than current alternatives and with numerous clinical indications.
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